Which treatment for nonalcoholic fatty liver disease?

被引：9

作者：

Moscatiello, S.

Marzocchi, R.

Villanova, N.

Bugianesi, E.

Marchesini, G. ^{[1
]}

机构：

[1] Alma Mater Studiorum Univ Bologna, Policlin S Orsola, Unit Clin Dietet, I-40138 Bologna, Italy

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2008年 / 8卷 / 08期

关键词：

D O I：

10.2174/138955708784912193

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Subjects with nonalcoholic fatty liver disease are at risk of progressive liver failure. Lifestyle changes including weight-loss strategies and increased physical activity remain the first-line approach, but a few pharmacological treatments have also been successfully tested. Several drugs improve biochemistry, only a few improve histology; in all cases, the results were not sustained after treatment stop. Pharmacological treatment is not so far indicated outside controlled clinical trials with histological outcomes.

引用

收藏

页码：767 / 775

页数：9

相关论文

共 100 条

[31] Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease [J].

Facchini, FS ;

Hua, NW ;

Stoohs, RA .

GASTROENTEROLOGY, 2002, 122 (04) :931-939

[32] Clinical features and natural history of nonalcoholic steatosis syndromes [J].

Falck-Ytter, Y ;

Younossi, ZM ;

Marchesini, G ;

McCullough, AJ .

SEMINARS IN LIVER DISEASE, 2001, 21 (01) :17-26

[33] Iron and insulin resistance [J].

Fargion, S ;

Dongiovanni, P ;

Guzzo, A ;

Colombo, S ;

Valenti, L ;

Fracanzani, AL .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 :61-63

[34] Apoptosis in alcoholic and nonalcoholic steatohepatitis [J].

Feldstein, AE ;

Gores, GJ .

FRONTIERS IN BIOSCIENCE-LANDMARK, 2005, 10 :3093-3099

[35] Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis [J].

Feldstein, AE ;

Canbay, A ;

Angulo, P ;

Taniai, M ;

Burgart, LJ ;

Lindor, KD ;

Gores, GJ .

GASTROENTEROLOGY, 2003, 125 (02) :437-443

[36] A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients [J].

Gomez-Dominguez, E. ;

Gisbert, J. . P. ;

Moreno-Monteagudo, J. A. ;

Garcia-Buey, L. ;

Moreno-Otero, R. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (11) :1643-1647

[37]

GUMA G, 1997, HEPATOLOGY, V26, pA387

[38] A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients [J].

Harrison, SA ;

Fincke, C ;

Helinski, D ;

Torgerson, S ;

Hayashi, P .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (06) :623-628

[39]

Harrison SA, 2003, AM J GASTROENTEROL, V98, P2485, DOI 10.1111/j.1572-0241.2003.08699.x

[40]

Harrison SA, 2003, AM J GASTROENTEROL, V98, P926, DOI [10.1016/S0002-9270(03)00039-X, 10.1111/j.1572-0241.2003.07375.x]

← 1 2 3 4 5 6 7 8 9 10 →